Pfizer Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Pfizer Inc Unternehmen

Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

Pfizer Inc Informationen



BörsenkürzelPFE

Name des UnternehmensPfizer Inc

IPO-datumFeb 22, 2080

CEOBourla (Albert)

Anzahl der mitarbeiter81000

WertpapierartOrdinary Share

GeschäftsjahresendeFeb 22

Addresse66 Hudson Boulevard East

StadtNEW YORK

BörseNASDAQ OMX NASDAQ Basic NYSE

LandUnited States of America

Postleitzahl10001-2192

Telefon12127332323

Websitehttps://www.pfizer.com/

BörsenkürzelPFE

IPO-datumFeb 22, 2080

CEOBourla (Albert)

Führungskräfte von Pfizer Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Albert Bourla, Ph.D.

Chairman of the Board, Chief Executive Officer

372.89K

+35552.00%

Mr. Douglas M. Lankler

Executive Vice President, Chief Legal Officer

161.04K

+12289.00%

Ms. Sally Susman

Executive Vice President, Chief Corporate Affairs Officer

95.94K

+7298.00%

Mr. Michael (Ike) Mcdermott

Executive Vice President, Chief Global Supply Officer

70.77K

-553.00%

Mr. Ronald E. Blaylock

Independent Director

32.46K

+19457.00%

Ms. Lidia L. Fonseca

Executive Vice President, Chief Digital and Technology Officer

30.96K

+30962.00%

Mr. Aamir Malik

Executive Vice President, Chief US Commercial Officer

29.55K

+29174.00%

Ms. Payal Sahni

Executive Vice President, Chief People Experience Officer

24.85K

+1543.00%

Dr. Scott Gottlieb, M.D.

Independent Director

10.00K

--

Mr. Cyrus Taraporevala

Independent Director

10.00K

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Albert Bourla, Ph.D.

Chairman of the Board, Chief Executive Officer

372.89K

+35552.00%

Mr. Douglas M. Lankler

Executive Vice President, Chief Legal Officer

161.04K

+12289.00%

Ms. Sally Susman

Executive Vice President, Chief Corporate Affairs Officer

95.94K

+7298.00%

Mr. Michael (Ike) Mcdermott

Executive Vice President, Chief Global Supply Officer

70.77K

-553.00%

Mr. Ronald E. Blaylock

Independent Director

32.46K

+19457.00%

Ms. Lidia L. Fonseca

Executive Vice President, Chief Digital and Technology Officer

30.96K

+30962.00%

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Eliquis alliance revenues and direct sales

2.02B

12.10%

Prevnar family

1.74B

10.46%

Vyndaqel family

1.59B

9.55%

Paxlovid

1.23B

7.36%

Comirnaty

1.15B

6.91%

Andere

8.93B

53.62%

Nach RegionUSD

Name

Umsatz

Anteil

United States

10.69B

64.19%

Developed Markets

3.70B

22.19%

Emerging Markets

2.27B

13.61%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Eliquis alliance revenues and direct sales

2.02B

12.10%

Prevnar family

1.74B

10.46%

Vyndaqel family

1.59B

9.55%

Paxlovid

1.23B

7.36%

Comirnaty

1.15B

6.91%

Andere

8.93B

53.62%

Aktionärsstatistik

Aktualisiert: Sun, Nov 16

Aktionäre

Aktionärstypen

Aktionäre

Anteil

The Vanguard Group, Inc.

9.47%

State Street Investment Management (US)

5.26%

BlackRock Institutional Trust Company, N.A.

5.17%

Geode Capital Management, L.L.C.

2.27%

Norges Bank Investment Management (NBIM)

1.65%

Andere

76.18%

Aktionäre

Anteil

The Vanguard Group, Inc.

9.47%

State Street Investment Management (US)

5.26%

BlackRock Institutional Trust Company, N.A.

5.17%

Geode Capital Management, L.L.C.

2.27%

Norges Bank Investment Management (NBIM)

1.65%

Andere

76.18%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

33.58%

Investment Advisor/Hedge Fund

23.23%

Research Firm

2.99%

Pension Fund

2.49%

Sovereign Wealth Fund

1.72%

Bank and Trust

1.61%

Insurance Company

1.27%

Hedge Fund

0.92%

Holding Company

0.05%

Andere

32.14%

Institutionelle Beteiligung



Aktualisiert: Thu, Jan 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

4742

3.86B

67.83%

-80.87M

2025Q3

4830

3.80B

66.84%

-140.11M

2025Q2

4945

3.85B

67.75%

-89.09M

2025Q1

5074

3.86B

67.90%

-51.97M

2024Q4

5153

3.84B

67.74%

-83.26M

2024Q3

5005

3.85B

67.99%

-51.77M

2024Q2

5026

3.84B

67.75%

-120.77M

2024Q1

5032

3.89B

68.71%

-120.39M

2023Q4

5089

3.97B

70.25%

-96.67M

2023Q3

4952

4.00B

70.89%

-71.80M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

531.51M

9.35%

+833.15K

+0.16%

Sep 30, 2025

State Street Investment Management (US)

299.09M

5.26%

+2.79M

+0.94%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

294.15M

5.17%

+5.26M

+1.82%

Sep 30, 2025

Geode Capital Management, L.L.C.

129.01M

2.27%

+1.54M

+1.20%

Sep 30, 2025

Norges Bank Investment Management (NBIM)

93.65M

1.65%

+5.87M

+6.68%

Jun 30, 2025

Wellington Management Company, LLP

60.46M

1.06%

-16.54M

-21.48%

Sep 30, 2025

State Farm Insurance Companies

57.66M

1.01%

+71.50K

+0.12%

Sep 30, 2025

MFS Investment Management

54.96M

0.97%

-17.80M

-24.46%

Sep 30, 2025

BlackRock Asset Management Ireland Limited

52.35M

0.92%

-2.30M

-4.21%

Sep 30, 2025

BlackRock Investment Management (UK) Ltd.

50.76M

0.89%

+1.88M

+3.85%

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Mon, Dec 1

Name

Anteil

VanEck Pharmaceutical ETF

10.43%

First Trust NASDAQ Pharmaceuticals ETF

7.73%

Franklin US Dividend Booster Index ETF

7.39%

First Trust Morningstar Dividend Leaders Index Fund

6.54%

WBI Power Factor High Dividend ETF

4.87%

Invesco Pharmaceuticals ETF

4.84%

Coastal Compass 100 ETF

4.8%

iShares U.S. Pharmaceuticals ETF

4.43%

Amplify Weight Loss Drug & Treatment ETF

4.14%

Roundhill GLP-1 & Weight Loss ETF

3.73%

VanEck Pharmaceutical ETF

Anteil10.43%

First Trust NASDAQ Pharmaceuticals ETF

Anteil7.73%

Franklin US Dividend Booster Index ETF

Anteil7.39%

First Trust Morningstar Dividend Leaders Index Fund

Anteil6.54%

WBI Power Factor High Dividend ETF

Anteil4.87%

Invesco Pharmaceuticals ETF

Anteil4.84%

Coastal Compass 100 ETF

Anteil4.8%

iShares U.S. Pharmaceuticals ETF

Anteil4.43%

Amplify Weight Loss Drug & Treatment ETF

Anteil4.14%

Roundhill GLP-1 & Weight Loss ETF

Anteil3.73%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 36.47B USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Dec 12, 2025

PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 06, 2026 going ex on Jan 23, 2026

Jan 23, 2026

Mar 06, 2026

Jan 23, 2026

Oct 09, 2025

PFE.NB Final Cash Dividend of gross USD 0.43 paid on Dec 01, 2025 going ex on Nov 07, 2025

Nov 07, 2025

Dec 01, 2025

Nov 07, 2025

Jun 25, 2025

PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Sep 02, 2025 going ex on Jul 25, 2025

Jul 25, 2025

Sep 02, 2025

Jul 25, 2025

Apr 23, 2025

PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Jun 13, 2025 going ex on May 09, 2025

May 09, 2025

Jun 13, 2025

May 09, 2025

Dec 12, 2024

PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 07, 2025 going ex on Jan 24, 2025

Jan 24, 2025

Mar 07, 2025

Jan 24, 2025

Oct 09, 2024

PFE.NB Final Cash Dividend of gross USD 0.42 paid on Dec 02, 2024 going ex on Nov 08, 2024

Nov 08, 2024

Dec 02, 2024

Nov 08, 2024

Jun 26, 2024

PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Sep 03, 2024 going ex on Jul 26, 2024

Jul 26, 2024

Sep 03, 2024

Jul 26, 2024

Apr 24, 2024

PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Jun 14, 2024 going ex on May 09, 2024

May 10, 2024

Jun 14, 2024

May 09, 2024

Dec 14, 2023

PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Mar 01, 2024 going ex on Jan 25, 2024

Jan 26, 2024

Mar 01, 2024

Jan 25, 2024

Oct 04, 2023

PFE.NB Final Cash Dividend of gross USD 0.41 paid on Dec 04, 2023 going ex on Nov 09, 2023

Nov 10, 2023

Dec 04, 2023

Nov 09, 2023

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten